Functional variants in the sucrase–isomaltase gene associate with increased risk of irritable bowel syndrome by Henström, Maria et al.
ORIGINAL ARTICLE
Functional variants in the sucrase–isomaltase gene
associate with increased risk of irritable bowel
syndrome
Maria Henström,1 Lena Diekmann,2 Ferdinando Bonfiglio,1 Fatemeh Hadizadeh,1
Eva-Maria Kuech,2 Maren von Köckritz-Blickwede,2 Louise B Thingholm,3
Tenghao Zheng,1 Ghazaleh Assadi,1 Claudia Dierks,4 Martin Heine,2 Ute Philipp,4
Ottmar Distl,4 Mary E Money,5,6 Meriem Belheouane,7,8 Femke-Anouska Heinsen,3
Joseph Rafter,1 Gerardo Nardone,9 Rosario Cuomo,10 Paolo Usai-Satta,11
Francesca Galeazzi,12 Matteo Neri,13 Susanna Walter,14 Magnus Simrén,15,16
Pontus Karling,17 Bodil Ohlsson,18,19 Peter T Schmidt,20 Greger Lindberg,20
Aldona Dlugosz,20 Lars Agreus,21 Anna Andreasson,21,22 Emeran Mayer,23
John F Baines,7,8 Lars Engstrand,24 Piero Portincasa,25 Massimo Bellini,26
Vincenzo Stanghellini,27 Giovanni Barbara,27 Lin Chang,23 Michael Camilleri,28
Andre Franke,3 Hassan Y Naim,2 Mauro D’Amato1,29,30
ABSTRACT
Objective IBS is a common gut disorder of uncertain
pathogenesis. Among other factors, genetics and certain
foods are proposed to contribute. Congenital sucrase–
isomaltase deficiency (CSID) is a rare genetic form of
disaccharide malabsorption characterised by diarrhoea,
abdominal pain and bloating, which are features
common to IBS. We tested sucrase–isomaltase (SI) gene
variants for their potential relevance in IBS.
Design We sequenced SI exons in seven familial cases,
and screened four CSID mutations (p.Val557Gly, p.
Gly1073Asp, p.Arg1124Ter and p.Phe1745Cys) and a
common SI coding polymorphism (p.Val15Phe) in a
multicentre cohort of 1887 cases and controls. We
studied the effect of the 15Val to 15Phe substitution on
SI function in vitro. We analysed p.Val15Phe genotype in
relation to IBS status, stool frequency and faecal
microbiota composition in 250 individuals from the
general population.
Results CSID mutations were more common in patients
than asymptomatic controls (p=0.074; OR=1.84) and
Exome Aggregation Consortium reference sequenced
individuals (p=0.020; OR=1.57). 15Phe was detected in
6/7 sequenced familial cases, and increased IBS risk in
case–control and population-based cohorts, with best
evidence for diarrhoea phenotypes (combined
p=0.00012; OR=1.36). In the population-based sample,
15Phe allele dosage correlated with stool frequency
(p=0.026) and Parabacteroides faecal microbiota
abundance (p=0.0024). The SI protein with 15Phe
exhibited 35% reduced enzymatic activity in vitro
compared with 15Val (p<0.05).
Conclusions SI gene variants coding for
disaccharidases with defective or reduced enzymatic
activity predispose to IBS. This may help the
identification of individuals at risk, and contribute to
personalising treatment options in a subset of patients.
Significance of this study
What is already known on this subject?
▸ IBS shows genetic predisposition, but specific
causative genes have not been unequivocally
identified.
▸ Certain foods, particularly carbohydrates, are
among the proposed triggers of IBS symptoms,
at least in some patients.
▸ The sucrase–isomaltase (SI) gene, which is
mutated in hereditary recessive forms of
sucrose intolerance (congenital sucrase–
isomaltase deficiency (CSID)) characterised by
diarrhoea, represents an excellent candidate to
play a role in IBS predisposition.
What are the new findings?
▸ Although rare, CSID mutations with known
defective disaccharidase (SI) properties are
found more often in patients with IBS than
controls.
▸ A common SI variant (15Phe), which shows
reduced enzymatic activity in vitro, is strongly
associated with increased risk of IBS.
How might it impact on clinical practice in
the foreseeable future?
▸ Screening for functional SI genetic variants may
help the identification of subsets of patients
with suboptimal carbohydrate (disaccharide)
digestion rates.
▸ This holds potential for stratifying patients with
IBS and personalising treatment options in
those with SI genetic defects.
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INTRODUCTION
IBS is the most common gut disorder, affecting more than 10%
of the general population in Westernised countries; it is asso-
ciated with significant healthcare expenditure and considerably
affects patients’ quality of life.1 2 IBS is a functional GI disorder
(FGID), diagnosed and classified according to expert consensus
guidelines, the Rome criteria, based on recurrent symptoms
including abdominal discomfort or pain associated with diar-
rhoea (IBS-D), constipation (IBS-C) or mixed symptoms
(IBS-M).3 The aetiology of IBS is unknown, although psycho-
logical stressors, prior infections, dietary irritants, gut dysbiosis,
epithelial barrier dysfunction and mucosal immune activation
are among the recognised risk factors.4 Genetic predisposition
has been demonstrated in classical family/twin studies and epi-
demiological surveys, but unequivocal susceptibility genes have
yet to be identified.5 Because of incomplete understanding of
the mechanisms underpinning IBS pathophysiology, effective
treatment options are limited and primarily aimed at targeting
symptoms, resulting in suboptimal efficacy.
The role of nutrition and dietary factors is increasingly recog-
nised in IBS. Patients (particularly IBS-D) often report postpran-
dial symptoms,6 and many IBS sufferers claim that certain foods
are the triggering factors.7 Avoidance of carbohydrates due to
perceived maldigestion is common, and a diet low in ferment-
able oligosaccharides, disaccharides, monosaccharides and
polyols (FODMAPs, which are poorly absorbed in the small
intestine) has been proposed as effective in reducing IBS symp-
toms.8 9 At least in some patients, the food–symptom relation
may involve malabsorption of carbohydrates due to inefficient
enzymatic breakdown of polysaccharides, which may find indir-
ect support in the observed symptom improvement in patients
with postprandial IBS-D treated with pancrealipase,10 and the
detection of disaccharidase deficiency in children with FGID.11
Sucrase–isomaltase (SI) deficiency (also called sucrose intoler-
ance) is a form of carbohydrate malabsorption characterised by
diarrhoea, abdominal pain and bloating, which are features
common to IBS-D. The symptoms result from defective glucosi-
dase (disaccharidase) activity of the SI enzyme in the small intes-
tine.12 This enzyme is key to the degradation of starch and
sugars digested daily,13 and its functional impairment leads to
colonic accumulation of unabsorbed carbohydrates causing
osmotic diarrhoea. At the same time, this induces a shift in gut
microbiota-associated activities of carbohydrate metabolism and
fermentation, with increased production of short-chain fatty
acids and gases, which contribute to symptom generation. In the
congenital form of SI deficiency (congenital sucrase–isomaltase
deficiency (CSID)), patients harbour two defective copies of the
SI gene due to recessive homozygous or compound heterozy-
gous mutations that abolish or dramatically reduce enzymatic
activity.14 15 CSID usually manifests early in life, but the pheno-
type and severity of symptoms can vary depending on the spe-
cific nature and position (sucrase or isomaltase domain) of
different SI mutations and their homozygous or heterozygous
combinations.16 In addition, adult patients, previously misdiag-
nosed with IBS, have been described.17 18 Overall, this speaks
for a potentially higher clinical impact of SI genetic variation
than that based solely on the detection of rare homozygous
mutations in patients with CSID, evoking the hypothesis that SI
functional polymorphisms may contribute also to IBS predispos-
ition and symptom generation. If confirmed, this may have
important implications in the management of IBS because of
the potential for dietary intervention or enzyme supplementa-
tion in a subset of genetically exposed patients. To test this
hypothesis, we performed a series of independent experiments:
(1) sequencing of the entire SI coding region in seven familial
cases of severe postprandial IBS-D; (2) detailed in vitro func-
tional characterisation of a common coding variant leading to
the amino acid change p.Val15Phe in the SI protein; (3) geno-
typing and association testing of the most common known
CSID mutations,19 and the p.Val15Phe variant in 1887 indivi-
duals from four independent cohorts of IBS cases and controls;
(4) in a small Swedish general population sample, pilot analyses
of correlation between p.Val15Phe genotype and (i) IBS status
(ii) stool frequency and (iii) faecal microbiota composition. The
results obtained from these experiments support a role for SI
genetic variation in IBS.
MATERIALS AND METHODS
Study subjects
IBS probands
Eight Caucasian individuals, namely seven postprandial IBS-D
cases (Rome criteria) and one asymptomatic relative, from four
unrelated families were selected for sequencing of the SI gene
(see online supplementary figure S1). Two of the symptomatic
patients were parents of two of the probands. Patients experi-
enced meal-related symptoms for more than 2 years and were
currently using digestive enzyme supplements to reduce post-
prandial symptoms (described more in detail in the online
supplementary methods).
IBS case–control cohorts
We studied a total of 1031 IBS cases and 856 controls, all
non-Hispanic/Latino whites from four independent cohorts
from Sweden, Italy and USA, who have been described in detail
elsewhere and already included in previous genetic studies.20–25
Their demographics and clinical characteristics are reported in
table 1, and detailed information is provided in the online
supplementary methods and table S1.
PopCol participants
The Population-based Colonoscopy study (PopCol) is a cohort
representative of the general population from Stockholm,
Sweden, which includes a data-rich set of individuals with avail-
able information from bowel symptom questionnaires, 1-week
and 2-week bowel pattern diaries, clinical records from gastro-
enterology visits, blood and stool samples for genetic and micro-
biota analyses, and histology from biopsies obtained at
ileocolonoscopy (table 1, online supplementary table S1 and
online supplementary methods).26 27
All study participants provided informed consent, and the
study protocols were approved by local ethics committees.
Sequencing (SI and 16S) and genotyping
Sequencing of the SI coding region was performed as described
previously28 and in the online supplementary methods. For the
microbiota studies, faecal bacterial DNA was extracted from
each sample and 16S rRNA gene amplicon (V1–V2 region)
sequencing was performed on the MiSeq platform (Illumina,
USA). Read coverage was normalised to 10 000 read per
sample, and taxonomic classification was performed as
described in the online supplementary methods. Targeted geno-
typing of known CSID mutations and the p.Val15Phe
rs9290264 single nucleotide polymorphism (SNP) in patients
with IBS and controls was carried out using the iPLEX chemis-
try on the MassARRAY platform (Sequenom, USA), while p.
Val15Phe PopCol genotypes were extracted from available
HumanOmniExpressExome data (Illumina, USA).
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Measurement of SI enzymatic activity in vitro
Functional characterisation of the polymorphism p.Val15Phe
was obtained in a well-established SI model system,29 by transi-
ently transfecting monkey fibroblast COS-1 cells with cDNA
vectors encoding the 15Val and 15Phe variants. Sucrase activity
was measured using sucrose as a substrate as previously
described.30 Briefly, immunoprecipitates from 15Val or 15Phe
transfected cells were incubated with sucrose (28 mmol/L) for
1 hour at 37°C, and the amount of glucose generated from
sucrose hydrolysis was detected using the glucose oxidation-
phenol aminopyrine (GOD-PAP) monoreagent method (Axiom
GmbH, Germany). To control for transfection efficiency, 15Val
and 15Phe activities were normalised relative to the specific SI
protein amounts, as measured by immunoblot analysis of the
corresponding immunoprecipitates. A detailed description of
the protocols adopted for the full in vitro functional character-
isation of the p.Val15Phe polymorphism is reported in the
online supplementary methods.
In silico and statistical analyses
PHRED-like scores from the Combined Annotation-Dependent
Depletion (CADD) database V.1.3 were used for predicting func-
tional effects of known CSID mutations and SI common coding
polymorphisms (see online supplementary methods).31
One-sided (testing predisposing risk effects) association analysis
of CSID mutations carriage was performed using 2×2 contin-
gency table statistics (Fisher’s exact test and χ2 as appropriate)
in IBS cases versus (i) controls and (ii) reference genotypes from
publicly available large-scale sequence data for individuals of
European descent (http://exac.broadinstitute.org/).19 Association
with the p.Val15Phe variant was tested on pooled data using
logistic regression under a (best powered) additive genetic
model adjusting for sex and batch (recruitment centre). A
meta-analysis of results from individual cohorts was also carried
out to verify the absence of statistical heterogeneity (see online
supplementary methods). Spearman’s correlation was used to
assess the relationship between 15Phe copy number, stool fre-
quency and gut microbiota composition in the PopCol cohort.
Functional differences in 15Val and 15Phe SI protein properties
in in vitro experiments were evaluated using Student’s t-tests.
More detailed descriptions of the statistical procedures are
reported in the online supplementary methods.
RESULTS
Sequencing of the SI gene in IBS families
Seven familial cases and one asymptomatic relative (control)
from four IBS-D families were included in the SI sequencing
effort (see online supplementary figure S1 and online
supplementary methods), aiming to identify SI mutations or var-
iants of potential relevance to IBS. No new variants were
detected in this experiment (data not shown), and all sequenced
family members were homozygous for SI reference coding
alleles, except at two sites, namely missense SNPs rs9290264
(p.Val15Phe) and rs9283633 (p.Thr231Ala) (see
online supplementary figure S1). Together with rs4855271
(p.Met1523Ile), rs9290264 and rs9283633 are the only
common (minor allele frequency >0.01) missense SNPs in the
SI gene (http://exac.broadinstitute.org/gene/ENSG00000090402
and figure 1). No conclusive experimental data exist on
the potential functional effects of these amino acid changes on
SI properties. However, opposite to p.Thr231Ala and
p.Met1523Ile that result in benign changes, computational pre-
dictions at the CADD database (see online supplementary
methods) rank p.Val15Phe among the top 1% most deleterious
amino acid substitutions in the human genome,31 similar to
known CSID mutations (figure 1). Although also common in
the general population (allele frequency=0.3), the 15Phe was
present in 6/7 (five heterozygous and one homozygous)
sequenced affected family members, and cosegregated with IBS
in the two families where parental SI sequence data were also
Table 1 Demographics and clinical characteristics of study subjects
Case–control cohorts
Sweden Italy US (Mayo) US (UCLA) Total
IBS CTRL IBS CTRL IBS CTRL IBS CTRL IBS CTRL
N 387 355 319 255 187 114 138 132 1031 856
Mean age, year 42 42.5 39.6 34.8 47.9 46.6 35.0 33.5 41.4 39.4
% F:M 82:18 43:57 73:27 68:32 91:9 67:33 75:25 58:42 80:20 56:44
IBS-D 127 159 89 42 417
IBS-C 95 128 56 45 324
IBS-M 162 32 41 34 269
IBS-U 3 0 1 17 321
PopCol Total IBS* CTRL* Microbiota Diary
N 250 30 163 136 133
Mean age, year 53.6 51.6 54.7 54.8 54.7
% F:M 64:36 60:40 59:41 62:38 65:35
IBS-D 11
IBS-C 5
IBS-M 9
IBS-U 5
*IBS cases (IBS) and asymptomatic controls (CTRL) were identified based on questionnaire data according to Rome criteria.
Diary, subjects with available daily recordings of defaecation patterns used for correlation analysis with the Val15Phe variant and stool frequency; Microbiota, subjects with available
faecal 16S sequencing data; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS; IBS-M, IBS mixed phenotype; IBS-U, unclassified IBS; PopCol, Population-based
Colonoscopy Study; UCLA, University of California, Los Angeles.
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available (see online supplementary figure S1). Based on the
above information, we set to undertake a functional in vitro
characterisation of the 15Phe coding allele.
Functional characterisation of the Phe15Val coding
polymorphism
Adopting an established in vitro model previously used to study
known CSID mutants, SI 15Val and 15Phe protein variants
were individually expressed in COS-1 cells and tested for poten-
tial differences in their functional properties. The patterns of
glycosylation and trypsin digestion, as well as the intracellular
distribution and trafficking kinetics, appeared to be similar for
the two variants (not shown). However, when tested for their
relative cell surface expression, which requires association with
lipid rafts through the stalk region adjacent to residue 15 where
the 15Phe substitution occurs, the two variants’ behaviour was
consistently different under a series of experimental conditions,
and the 15Phe variant showed a 20% reduction of cell surface
localisation compared with 15Val (figure 2A–C). Of note, the
15Phe SI variant had an overall 35% reduction of enzyme activ-
ity compared with 15Val, after normalisation and quantification
of immunoprecipitated proteins from COS-1 transfected cells
(p<0.05; figure 2D).
Association analysis of CSID mutations and the 15Phe
variant in IBS cases and controls
A total of 1887 individuals from four independent IBS case–
control cohorts were included in the analysis of the SI gene in
IBS (table 1). The four most common known CSID mutations
(p.Val557Gly, p.Gly1073Asp, p.Arg1124Ter and p.Phe1745Cys)
were genotyped in these cohorts and tested for their potential
to confer IBS risk. Twenty-two heterozygous IBS cases and ten
heterozygous controls were identified, consistent with a trend
for patients with IBS to have nearly two times higher odds of
carrying a CSID mutation than asymptomatic controls
(p=0.074, OR=1.84; table 2). This finding (statistically weak
due to the control sample size likely inadequate to test rare var-
iants) could be consolidated by inspecting public data from a
reference panel of >30 000 sequenced European individuals
from the Exome Aggregation Consortium. As shown in table 2,
significant results were obtained both for p.Val577Gly and a
cumulative analysis of CSID mutations (p=0.0029, OR=2.11
and p=0.020, OR=1.57, respectively). The distribution of
mutations into different IBS subtypes was even for p.Val557Gly,
which maps to the isomaltase domain of the SI protein, though
the other mutations affecting the sucrase domain (p.
Gly1073Asp, p.Arg1124Ter and p.Phe1745Cys; figure 1) were
found only in patients with IBS-D and IBS-M (table 2). The IBS
predisposing potential of the 15Phe variant was also tested by
genotyping the entire sample for the rs9290264 (Val15Phe)
SNP. As shown in table 3, 15Phe was significantly associated
with increased risk of IBS in a logistic regression analysis of the
combined cohorts under an additive genetic model adjusted for
sex and recruitment centre (p=0.0030, OR=1.26). Similar find-
ings (associations and effect sizes) were obtained using a domin-
ant model, while recessive association testing yielded negative
results (data not shown). Of note, the strength of association
appeared to vary in different IBS subtypes, as 15Phe signifi-
cantly affected disease risk only in the subtypes characterised by
diarrhoea, and the D and M subtypes combined provided the
best evidence of association and stronger genetic risk effects
(p=0.00051, OR=1.34 for the IBS-D/IBS-M; table 3). Similar
IBS genetic risk effects were observed across all four datasets,
and a meta-analysis of associations from individual cohorts
yielded results identical to the pooled analyses and devoid of
statistical heterogeneity (Cochran’s Q range 0.55–0.97 and het-
erogeneity index I2=0 for all IBS traits; online supplementary
figure S2).
Analysis of the 15Phe variant in relation to bowel function
and microbiota in the general population
A data-rich subset of 250 individuals from the PopCol cohort
was studied to run pilot tests of the relevance of 15Phe in the
general population, in relation to bowel function, symptoms
and microbiota composition (table 1). Using Rome III criteria
extracted from questionnaire data, 30 IBS and 163 symptom-
free individuals were identified, and, despite small sample size, a
significant association was detected between 15Phe and
increased IBS risk, particularly IBS-M (p=0.017, OR=3.81;
table 3). Combining these data with the case–control results
Figure 1 Properties of sucrase–isomaltase (SI) mutants and common coding polymorphisms. Left: schematic representation of SI protein structure
and functional domains; the position of congenital sucrase–isomaltase deficiency (CSID) mutations and common coding variants is reported and
colour-coded according to their functional effects (red=damaging, green=benign). Right: the variants, corresponding dbSNP IDs (http://www.ncbi.
nlm.nih.gov/SNP), SI protein domain location (TM, transmembrane; I, isomaltase; S, sucrase), allele frequency, PHRED-like score (range 1–99, ranking
a variant relative to all possible substitutions in the human genome) and predicted functional consequences are reported. #Exome Aggregation
Consortium browser (http://exac.broadinstitute.org); ^Combined Annotation-Dependent Depletion database (http://cadd.gs.washington.edu/info). SNP,
single nucleotide polymorphism.
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further strengthened the evidence of association with IBS,
which was strongest in patients with diarrhoea from the IBS-M
and IBS-D subtypes (combined p=0.00012, OR=1.36; table 3).
In 133 PopCol individuals who had daily recordings of
defaecation patterns (see online supplementary methods), a sig-
nificant correlation (p=0.026) was observed between the
number of 15Phe copies and mean stool frequency, with homo-
zygous carriers showing the highest number of bowel
Figure 2 Functional characterisation of the p.Val15Phe coding polymorphism. COS-1 cells were transiently transfected with either 15Val or 15Phe
cDNAs and studied 48 hours after transfection. Individual values for 15Val and 15Phe cells from the same experiment are indicated with identical
symbols. Net differences are reported with red bars as per cent average relative to 15Val arbitrarily set as 100% reference. (A) Cell surface
localisation via immunofluorescence. Non-permeabilised cells were immunostained with a mixture of anti-sucrase–isomaltase (SI) antibodies and
Alexa 488 secondary antibody, and analysed by confocal laser scanning microscopy on the xy (scale bar 25 mm) and xz planes (scale bar 10 mm).
(B) Quantification of cell surface expression. SI surface proteins were labelled with biotin and immunoprecipitated using anti-Si antibodies after cell
lysis. Immunoprecipitates were divided into two equal aliquots and analysed by immunoblotting with either anti-SI or anti-streptavidin antibodies.
Relative quantification of surface-bound SI versus total cell SI was performed, and results are expressed in relation to values obtained for 15Val,
which is set to 100%. (C) Quantification of association with sphingolipid/cholesterol-rich microdomains (lipid rafts) via detergent-resistant membrane
(DRM) analysis. Following non-ionic detergent cell lysis, SI proteins were immunoprecipitated, fractionated by ultracentrifugation into insoluble
(pellet, raft) and soluble (supernatant, non-raft) fractions, and DRM association (raft) quantified by immunoblotting with anti-SI antibodies. (D)
Quantification of enzymatic activity. Sucrase activity was determined on immunoprecipitated SI proteins by measuring glucose release with the
GOD–PAP method, upon normalisation for total protein amount by immunoblotting. *p<0.05.
Table 2 Association of known CSID mutations with IBS
IBS
Subtypes
CTRLS
p Value* OR
ExAC
p Value* ORN=1031 N=856 N=31 402
p.Val577Gly 14 4 IBS-D, 5 IBS-M, 5 IBS-C 6 0.12 1.95 203 0.0029 2.11
p.Gly1073Asp 3 3 IBS-D 3 0.57 0.83 109 0.42 0.89
p.Arg1124Ter 1 1 IBS-D 0 – – 8 0.077 4.04
p.Phe1745Cys 4 1 IBS-D, 2 IBS-M, 1 IBS-U 1 0.25 3.33 110 0.42 1.11
Any mutation 22 9 IBS-D, 7 IBS-M, 5 IBS-C, 1 IBS-U 10 0.074 1.84 430 0.020 1.57
*p Value for carriage of SI mutations in IBS cases (IBS) versus controls (CTRLS) and versus ExAC-sequenced individuals of European descent (ExAC).
CSID, Congenital sucrase–isomaltase deficiency; ExAC, Exome Aggregation Consortium; SI, sucrase–isomaltase; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS;
IBS-M, IBS mixed phenotype; IBS-U, unclassified IBS. Significant p Values (<0.05) highlighted in bold italics.
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movements per day (figure 3). However, no significant findings
were obtained from a similar analysis assessing the relationship
with stool consistency (measured on the Bristol Stool Form
Scale, not shown). Faecal microbiota data (16S rRNA gene
sequencing) were available for 136 PopCol-genotyped indivi-
duals and used to test the potential relation between host p.
Val15Phe genotype and gut bacterial community composition
(see online supplementary methods). By testing the 20 most
abundant genera (see online supplementary table S2), we
detected Bonferroni-corrected significant inverse correlation
between the number of 15Phe copies and the abundance of
Parabacteroides (p=0.0024; online supplementary figure S3).
This was independent of IBS status and bowel complaints, as
the correlation was still significant when tested in the subset of
90 PopCol symptom-free individuals (data not shown).
DISCUSSION
Our studies show that genetic variation in the SI gene is asso-
ciated with predisposition to IBS. We detected a twofold
increased risk of IBS in heterozygous carriers of known rare
CSID mutations. In addition, we detected genetic risk effects
attributable to a common coding variant, 15Phe at SNP
rs9290264, which cosegregated with IBS in some affected fam-
ilies, and was associated with increased disease odds in large
multinational IBS case–control cohorts and a pilot general
population sample. Although the current study only targeted a
few selected functional variants, the SI gene harbours >700
other (mostly rare) coding SNPs. Hence, SI polymorphisms may
influence IBS risk across different homozygous, heterozygous
and compound heterozygous allelic combinations, and future
resequencing and large-scale SI genotyping efforts may lead to
the identification of additional IBS risk variants.
As previously demonstrated for CSID mutants with estab-
lished SI defects, we also discovered that the 15Phe variant
imparts deficient enzymatic properties, resulting in 35%
reduced disaccharidase activity in vitro. Reduced carbohydrate
degradation rates may result in altered concentrations of starch
and sugar (sucrose) breakdown products across the intestine,
possibly including colonic increase of undigested disaccharides
not absorbed through the small intestine. In the large bowel,
osmotic luminal water release, microbiota composition and bac-
terial fermentation with gas production are all potentially
affected by these changes, with repercussions across diverse
bowel functions and, ultimately, symptoms.12 32 Of interest, in
the PopCol cohort, we observed a positive correlation between
the number of 15Phe copies and defaecation frequency, which
might be due to the effects on transit time mediated by similar
mechanisms. Hence, genotype-dependent reduction of SI disac-
charidase function appears to affect disease risk across a clinical
spectrum ranging from severe monogenic CSID forms to milder
complex IBS manifestations. The latter is particularly true for
IBS phenotypes characterised by diarrhoea, since, similar to the
effect of rare mutations in CSID, 15Phe shows strongest associ-
ation with the IBS-M and IBS-D subtypes while no significant
results were obtained for IBS-C. This notion is important
because it may help identify a subgroup of patients with IBS
with inherited predisposition to disaccharide maldigestion,
which holds potential for personalised approaches to their clin-
ical management.
Dietary carbohydrates are recognised triggers in many IBS
sufferers, who often implement food avoidance regimes in the
attempt to control or reduce their symptoms; thus, 52% of
1242 US patients with IBS who completed an IBS-Patient
Education Questionnaire in 2007 also believed IBS is caused by
lack of digestive enzymes.33 The results from our study provide
a biological basis for these beliefs, by demonstrating potential
mechanisms mediating the interplay between carbohydrate con-
sumption and enzymatic (SI) defects in their digestion. At the
same time, they also provide a rationale for future studies of
bowel symptoms in patients with IBS stratified according to SI
genotype in eventual trials of dietary exclusion of sucrose or
enzyme supplementation. With increasing recognition of the
importance of dietary factors in IBS, our results may contribute
to inform FODMAP-based strategies for the treatment of IBS.
For instance, it may be of high interest to further evaluate
Table 3 Association of the 15Phe variant with IBS
CTRL IBS IBS-C IBS-D IBS-M IBS-D/M
AF AF p Value OR AF p Value OR AF p Value OR AF p Value OR AF p Value OR
Case–control 0.264 0.306 0.0030* 1.26 0.279 0.42 1.09 0.312 0.0082 1.30 0.329 0.0026* 1.41 0.319 0.00051* 1.34
PopCol 0.29 0.417 0.045 1.89 0.400 0.45 1.72 0.409 0.20 1.88 0.556 0.017 3.81 0.475 0.013 2.50
Combined 0.268 0.309 0.0013* 1.27 0.281 0.39 1.10 0.314 0.0052 1.30 0.336 0.00057* 1.46 0.323 0.00012* 1.36
*p Value significant after Bonferroni correction for multiple comparisons (N=15), considering five traits (IBS, IBS-C, IBD-D, IBS-M and IBS-D/M) in three datasets (case–control cohorts,
PopCol and both combined). Significant p Values (<0.05) highlighted in bold italics.
AF, 15Phe allele frequency; CTRL, controls; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS; IBS-D/M, IBS-D+IBS-M; IBS-M, IBS mixed phenotype; p Value,
p Value from logistic regression adjusted for sex and batch (centre).
Figure 3 Correlation between p.Val15Phe genotype and stool
frequency. Mean (±SD) number of bowel movements per day (stool
frequency, y-axis) is reported for Population-based Colonoscopy Study
individuals (with available diary data) stratified according to the
genotype at the p.Val15Phe single nucleotide polymorphism site
(x-axis). The Spearman’s p value for the correlation test is also
reported.
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low-FODMAP diets or similarly effective traditional dietary
intervention strategies34 for their efficacy in reducing IBS symp-
toms by also taking into account patients’ SI genotype.
Finally, the results from our pilot study of PopCol microbiota
composition in relation to Val15Phe genotype are interesting,
because faecal microbiota concentration of Parabacteroides has
been shown to decrease with higher dietary carbohydrate intake,35
and this genus was under-represented in patients with IBS, at least
in some studies.36 37 Although unlikely of causative nature, the
negative correlation between 15Phe allele dosage and
Parabacteroides abundance may thus contribute to the identification
and further stratification of patients with IBS with SI disturbances.
In conclusion, we report the first experimental evidence
pointing to nutrigenetic mechanisms associated with IBS predis-
position and symptom generation. This holds potential for
stratifying patients with IBS and personalising treatment options
in those with SI genetic defects.
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